Trial · NCT02282813
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT) | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | 34 | participants | ||
| Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT) | CTAP101 Capsules (Not Randomized; 12 Mos Treatment) | 66 | participants | ||
| Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive | 30 | participants | ||
| Number of Participants in the Per Protocol Population With Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT) | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | 34 | participants | ||
| Number of Participants in the Per Protocol Population With Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT) | CTAP101 Capsules (Not Randomized; 12 Mos Treatment) | 64 | participants | ||
| Number of Participants in the Per Protocol Population With Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive | 29 | participants | ||
| Number of Participants in the Intent to Treat Population With Normal Serum 25-hydroxyvitamin D at End of Treatment (EOT) | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | 87 | participants | ||
| Number of Participants in the Intent to Treat Population With Normal Serum 25-hydroxyvitamin D at End of Treatment (EOT) | CTAP101 Capsules (Not Randomized; 12 Mos Treatment) | 124 | participants | ||
| Number of Participants in the Intent to Treat Population With Normal Serum 25-hydroxyvitamin D at End of Treatment (EOT) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive | 38 | participants | ||
| Number of Participants in the Per Protocol Population With NormalSerum 25-hydroxyvitamin D at End of Treatment (EOT) | CTAP101 Capsules (Not Randomized; 6 Mos Treatment) | 86 | participants | ||
| Number of Participants in the Per Protocol Population With NormalSerum 25-hydroxyvitamin D at End of Treatment (EOT) | CTAP101 Capsules (Not Randomized; 12 Mos Treatment) | 120 | participants | ||
| Number of Participants in the Per Protocol Population With NormalSerum 25-hydroxyvitamin D at End of Treatment (EOT) | CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive | 37 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02282813/results